Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

被引：0
|
作者：
Ades, Lionel [1 ]
Lebras, Fabien [1 ]
Sebert, Marie [1 ]
Kelaidi, Charikleia [1 ]
Lamy, Thierry [1 ]
Dreyfus, Francois [1 ]
Delaunay, Jacques [1 ]
Visanica, Sorin [1 ]
Turlure, Pascal [1 ]
Guerci, Agnes [1 ]
Cabrol, Marie Paule [1 ]
Banos, Anne [1 ]
Blanc, Michel [1 ]
Vey, Norbert [1 ]
Eclache, Virginie [1 ]
Chevret, Sylvie [1 ]
Fenaux, Pierre [1 ]
机构：
[1] Grp Francophone Myelodysplasies GFM, Bobigny, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：429 / 430
页数：2
相关论文
共 50 条
  • [1] Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)
    Ades, Lionel
    Prebet, Thomas
    Stamatoullas, Aspasia
    Recher, Christian
    Guieze, Romain
    Raffoux, Emmanuel
    Bouabdallah, Krimo
    Hunault, Mathilde
    Wattel, Eric
    Stalnikiewicz, Laure
    Toma, Andrea
    Dombret, Herve
    Vey, Norbert
    Boehrer, Simone
    Gardin, Claude
    Fenaux, Pierre
    BLOOD, 2010, 116 (21) : 225 - 225
  • [2] Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)
    Ades, Lionel
    Prebet, Thomas
    Stamatoullas, Aspasia
    Recher, Christian
    Guieze, Romain
    Raffoux, Emmanuel
    Bouabdallah, Krimo
    Hunault, Mathilde
    Wattel, Eric
    Stalnikiewicz, Laure
    Toma, Andrea
    Dombret, Herve
    Vey, Norbert
    Gardin, Claude
    Samey, Benedicte
    Chevret, Sylvie
    Fenaux, Pierre
    BLOOD, 2013, 122 (21)
  • [3] A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q-a Study By the Groupe Francophone Des Myelodysplasies (GFM)
    Ades, Lionel
    Recher, Christian
    Lejeune, Julie
    Stamatoullas, Aspasia
    Sebert, Marie
    Delaunay, Jacques
    Samey, Benedicte
    Bouabdallah, Krimo
    Braun, Thorsten
    Vey, Norbert
    Park, Sophie
    de Renzis, Benoit
    Chevret, Sylvie
    Fenaux, Pierre
    BLOOD, 2015, 126 (23)
  • [4] A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q-A Study By Groupe Francophone Des Myelodysplasies (GFM)
    Ades, Lionel
    Recher, Christian
    Stamatoullas, Aspasia
    Bouabdallah, Krimo
    Delaunay, Jacques
    Dreyfus, Francois
    Vey, Norbert
    de Renzis, Benoit
    Raffoux, Emmanuel
    Isnard, Francoise
    Samey, Benedicte
    Chaffaut, Cendrine
    Chevret, Sylvie
    Fenaux, Pierre
    BLOOD, 2013, 122 (21)
  • [5] Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies
    Ades, Lionel
    Le Bras, Fabien
    Sebert, Marie
    Kelaidi, Charikleia
    Lamy, Thierry
    Dreyfus, Francois
    Eclache, Virginie
    Delaunay, Jacques
    Bouscary, Didier
    Visanica, Sorin
    Turlure, Pascal
    Bresler, Agnes Guerci
    Cabrol, Marie-Paule
    Banos, Anne
    Blanc, Michel
    Vey, Norbert
    Delmer, Alain
    Wattel, Eric
    Chevret, Sylvie
    Fenaux, Pierre
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02): : 213 - 218
  • [6] SINGLE NUCLEOTIDE POLYMORPHISM ARRAY (SNP-A) KARYOTYPING IN LOWER RISK MYELODYSPLASTIC SYNDROMES (MDS), A STUDY BY THE GROUPE FRANCOPHONE DES MYELODYSPLASIES (GFM)
    Ben Abdelali, R.
    Gardin, C.
    Geoffroy, S.
    Nibourel, O.
    Peyrouze, P.
    Helvaut, N.
    Thepot, S.
    Rauzy, O. Beyne
    Prebet, T.
    Vey, N.
    Dreyfus, F.
    Fenaux, P.
    Cheok, M.
    Preudhomme, C.
    HAEMATOLOGICA, 2012, 97 : 133 - 133
  • [7] RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE
    Scharenberg, C.
    Karimi, M.
    Jansson, M.
    Walldin, G.
    Woll, P.
    Jacobsen, S. E.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2015, 39 : S84 - S84
  • [8] Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide
    Giagounidis, Aristoteles A.
    Haase, Sabine
    Platzbecker, Uwe
    Germing, Ulrich
    Lohrbacher, Vera
    Ehninger, Gerhard
    Aul, Carlo
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [9] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    List, A. F.
    Bennett, J. M.
    Sekeres, M. A.
    Skikne, B.
    Fu, T.
    Shammo, J. M.
    Nimer, S. D.
    Knight, R. D.
    Giagounidis, A.
    LEUKEMIA, 2014, 28 (05) : 1033 - 1040
  • [10] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    A F List
    J M Bennett
    M A Sekeres
    B Skikne
    T Fu
    J M Shammo
    S D Nimer
    R D Knight
    A Giagounidis
    Leukemia, 2014, 28 : 1033 - 1040
12345